The Delhi High Court has permitted Zydus Lifesciences to manufacture and sell a biosimilar version of the anti-cancer drug Nivolumab, overturning a previous injunction. A division bench cited public interest and the drug's life-saving nature, noting the patent's imminent expiry. Zydus' version is reportedly 70% cheaper than the original, marketed as Opdivo by Bristol-Myers Squibb (BMS). The court directed Zydus to maintain detailed sales records to protect BMS's rights pending the patent's expiration.